Proven efficacy allows for the use of CAYSTON as a standard of care for the maintenance of lung health

The Level A recommendation is for patients with moderate (FEV1 40%-69%) to severe (FEV1 <40%) disease and Pseudomonas aeruginosa (Pa) infection.5

CAYSTON is indicated in patients 7 years and older with an FEV1 between 25%-75% predicted.


Inhaled aztreonam (moderate to severe disease)


“For individuals with CF, 6 years of age and older, with moderate to severe lung disease and Pa persistently present in cultures of the airways, the CF Foundation strongly recommends the chronic use of inhaled aztreonam to improve lung functions…”

Certainty of Net Benefit*:


Estimate of Net Benefit*:




The overall strength of the evidence is based on the certainty of the magnitude of benefit defined as benefit minus harm.
Adapted from Table 4 From the Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. This is not a complete version of the table. See page 684 of publication for full table. CAYSTON-specific information only shown here.

High Quality of Evidence. The available evidence includes consistent results from well-designed, well-conducted studies in representative populations. This conclusion is therefore unlikely to be strongly affected by the results of future studies.